Antibody Discovery Now Prioritizes Manufacturing Feasibility Earlier in Drug Development Pipeline

Developers are increasingly incorporating manufacturability assessments during the antibody discovery phase rather than deferring these evaluations to later-stage development, according to FairJourney Bio executives. This shift reflects recognition that a biologically effective antibody that cannot be efficiently manufactured or administered provides no clinical value. Earlier developability screening can evaluate hundreds or thousands of candidate molecules and reduce costly surprises in downstream development phases that focus on manufacturing and regulatory aspects.

Antibody discovery traditionally followed a linear path where researchers identified molecules with strong binding and biological activity first, then handed them to manufacturing teams who discovered late-stage problems like poor stability or aggregation. These discoveries forced costly redesigns. By shifting developability assessments into the discovery phase, teams can now evaluate hundreds or thousands of candidates against manufacturing criteria simultaneously, allowing researchers to either select naturally superior molecules or address issues while costs remain low.

The approach also influences which discovery platforms teams select for each project. Rather than relying on a single antibody-generation method, organizations now match their discovery approach to the target's biological characteristics and the desired final product profile. This backwards-looking strategy—designing the discovery process with manufacturing and clinical administration in mind—aims to reduce unexpected obstacles that historically delayed programs moving from development into manufacturing scale-up.